Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

31 mars 2026 08h00 HE | Source: Proxygen GmbH

Proxygen Appoints Chiara Conti, Ph.D. as Chief Scientific Officer to Drive Clinical Translation and Expand Induced Proximity Platform Beyond Degradation

Vienna, Austria, March 31, 2026 (GLOBE NEWSWIRE) -- Vienna, Austria, March 31, 2026 - Proxygen, a biotechnology company pioneering the discovery of molecular glue degraders and next-generation...
20 févr. 2025 08h00 HE | Source: Photys Therapeutics, Incl

Photys Therapeutics Enters into Exclusive License Agreement with Polymed for Phase 1-Ready IRAK4 Degrader, Furthering its Proximity-based Pipeline and Mission

Photys Therapeutics exclusively in-licensed Phase 1-ready IRAK4 degrader from Polymed; plan to start Phase 1 later this year for autoimmune indications
18 déc. 2024 07h30 HE | Source: Photys Therapeutics, Incl

Photys Therapeutics Announces Research Collaboration with Novo Nordisk to Develop Induced Proximity PHICS Technology for Cardiometabolic Diseases

Photys and Novo Nordisk established a research collaboration to discover a new class of medicine for cardiometabolic diseases.